Dr. Keith Mitchell Skubitz, MD

Dr. Skubitz practices at M Health Fairview Heart Clinic in Saint Paul, Minnesota.

Dr. Skubitz's NPI, 1215019203, was assigned on October 19, 2006. Dr. Skubitz graduated from The Johns Hopkins University School of Medicine in 1976. Dr. Skubitz's Minnesota license number on file is 23896.

Dr. Skubitz's primary practice is M Health Fairview Heart Clinic, at 1700 University W Ave, Saint Paul, MN 55104 in Ramsey County. The practice phone is (612) 625-3600.

Dr. Skubitz's primary practice is M Health Fairview Heart Clinic in Saint Paul, Minnesota. Dr. Skubitz is also affiliated with M Health Fairview University of Minnesota Medical Center. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Skubitz to 4 more hospitals, 4 group practices and clinics and 3 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Skubitz practices, 9 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Skubitz's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Skubitz is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Skubitz's licenses on file in 2 states: Minnesota and Maryland.

CMS data shows 101 Medicare services from Dr. Skubitz across 2 procedure codes in 2024, all of them office visits, for 65 Medicare patients. Medicare paid $10,447 for them. Every service was in an office.

CMS counts 65 Medicare patients who saw Dr. Skubitz in 2024. The largest group is 65 to 74, with 33 patients. 66% of them have high blood pressure, and 65% have high cholesterol. Their average risk score is 2.01, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Skubitz's median patient age at 66, with 60% women.

In 2024, Dr. Skubitz wrote 113 Medicare Part D claims for 26 patients. 66% of them were for generic drugs. CMS names the drug for 26 of them, across 2 drugs with 11 or more claims each, at $231 in total drug cost. In 2023, CMS named 35 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Skubitz for performance year 2024, reported as part of a group. Dr. Skubitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Skubitz as offering telehealth.

Dmand AI links 156 papers to Dr. Skubitz, published from 2005 to 2025. 2016 was the busiest year, with 4. The most frequent topics are Neutrophils, Antibodies, Monoclonal and Antigens, CD. Dr. Skubitz has published most often in J Immunol. Dr. Skubitz's most frequent co-authors are Edward Y. Cheng, MD, Peter M. Anderson, MD, PhD and Thomas Woodrow Smith, MD.

Dmand AI links Dr. Skubitz to 2 clinical trials, 2 of them phase 2 studies. Conditions studied include Hemangiosarcoma, Liposarcoma and Neoplasms, Adipose Tissue. Northwestern University sponsors the most, 2.

CMS Open Payments shows 46 general payments to Dr. Skubitz from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 57% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $9,846.

Dmand AI lists 1 award for Dr. Skubitz, most recently CMS Stage 1 EHR in 2013.

Dr. Skubitz graduated from The Johns Hopkins University School of Medicine in 1976. Dr. Skubitz is a member of ASCO.

Dr. Skubitz is in network with 9 carriers, including Aetna, Medica and United Healthcare. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.